The cure for cancer has been one of the highest priorities of the medical world for decades, with scientists in both private and public fields trying their best to finally rid the world of the deadly disease. One group is closing in on a cure after publishing a paper indicating that they were able to reverse the conditions of terminally ill patients.
It’s well-known within the cancer community that the best way to head off cancer with current treatments is early diagnosis and an aggressive few rounds of chemotherapy, among other treatments. Once a patient reaches stage 4, their chances of survival diminish considerably. The US-based pharmaceutical company Kite Pharma is working on changing that and is making considerable headway.
The work that the company’s researchers were doing involve gene therapy and the trials yielded results that included terminally-ill patients going into remission after they were treated to just one round of trials. The trial itself lasted six months, with numerous subjects injected with modified T-cells.
For those who don’t know, T-cells are basically immune cells that are meant to destroy harmful invaders in the body. The genius of cancer cells is their ability to evade T-cells, which allows them to spread all over the body and multiply.
By genetically engineering these immune cells in order to make them more effective patrollers, they become better equipped to identify and eliminate cancer cells, Futurism reports. As a result, even patients who are at an advanced stage of the disease have a chance of cleansing their body of the illness.
As for the patients involved in the trials, they were divided based on which of the three types of non-Hodgkin lymphoma they had. Due to how advanced the stage of the cancer was in their bodies, most of the subjects were only given a few months to live. After the trials, many were given a second chance at life.


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 



